Open AccessLedipasvir and sofosbuvir for treatment of post- renal transplant hepatitis C infection: A case report withreview of literature
Author(s) -
Rishabh Jha,
Razia Fatima,
Sandeep Lakhtakia,
Ashwani Jha,
P Srikant,
Girish Narayan
Publication year - 2016
Publication title -
indian journal of nephrology/indian journal of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.317
H-Index - 24
eISSN - 1998-3662
pISSN - 0971-4065
DOI - 10.4103/0971-4065.163432
Subject(s) - medicine , sofosbuvir , gastroenterology , tacrolimus , ledipasvir , hepatitis c virus , hepatitis c , diabetes mellitus , viral load , renal transplant , immunology , transplantation , virus , ribavirin , endocrinology
Liver disease due to hepatitis C infection in renal transplant recipients is difficult to treat and often associated with reduced patient survival. A 43-year-old male, a renal allograft recipient, presented at 6 years follow-up with significant weight loss over 3 months. He was detected to have new onset diabetes mellitus together with hepatitis C virus (HCV) infection (genotype 1). His HCV load remained high despite the change of immuno-suppression from tacrolimus to cyclosporine. A decision to treat with a new anti-viral combination of ledipasvir and sofosbuvir for 12 weeks was taken. Within 3 weeks, his raised serum transaminases levels normalized and viral load became undetectable. At the end of 16 weeks, he continues to do well with normal renal function, has sustained remission from hepatitis C infection and resolution of diabetes.